Navigation Links
Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
Date:2/1/2012

erage; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain, and the FDA may not complete its review of the resubmission of the lorcaserin NDA by the PDUFA date; the FDA advisory committee meeting for lorcaserin may not be held as expected; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; Arena's submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... Oct. 17, 2014 UBM Medica US announces that ... online community and information resource for neurologists and other healthcare ... Alzheimer disease , with discussions of the latest developments ... million Americans have Parkinson disease , more than the total ... Lou Gehrig disease. Diagnosis can be difficult because there ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... MINNEAPOLIS, Oct. 29 The Minnesota State High School ... have teamed up to make the Minnesota State High School tournaments ... MSHSL has purchased eight mobile Automated External Defibrillators (AED) from HeartSine ... Cardiac Arrest (SCA), which is the leading cause of death in ...
... This holiday season, settle your stomach, relieve your wallet ... holidays, when many of us may suffer from occasional heartburn, a ... finds that you probably don,t need an expensive drug like Nexium, ... uses comparative effectiveness research to identify "Best Buys" based on safety, ...
Cached Medicine Technology:Minnesota High School Tournament Sidelines to be More Secure From Sudden Cardiac Arrest 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides ... its latest designs of 2014 mother of the ... outfits are offered with big discounts, up to 70% ... 30 can enjoy this special offer. , Owing ... has become one of the leading brands in the ...
(Date:10/19/2014)... SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem ... eventually lead to new treatments, a new study suggests. ... functioning human intestinal tissue in a lab dish. They ... model for studying intestinal disorders, according to the researchers. ... many diseases and conditions that can cause intestinal failure, ...
(Date:10/19/2014)... Nearly 9,000 transvaginal mesh lawsuits ( ... Johnson’s Ethicon unit have now been centralized in New ... are continuing to move forward, Bernstein Liebhard LLP reports. ... over products part of Ethicon Inc.’s line of Gynecare ... 11th, 2014, which showed an additional 1,600 claims now ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4
... 16 (HealthDay News) -- Women with rheumatoid arthritis or ... hoped for, according to a new study. These ... cause fertility problems and miscarriage, researchers said. Lupus ... and organs. Rheumatoid arthritis leads to painful joint inflammation. ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... of blood clots in people undergoing certain cancer treatments, ... treated with chemotherapy, they have an increased risk of ... dangerous, and have the potential to cause heart attacks ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Feb. ... also help problem drinkers cut their alcohol consumption, a ... drug curbs drinking is not fully understood, but its ... of sadness and nausea, thereby blunting the pleasurable effects ...
... HealthDay Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- ... require driver,s education before getting a license, about one-third ... half fail to undergo any formal behind-the-wheel training. ... records were especially unlikely to have received driver,s ed ...
... 15, 2012 California reported the largest decline in drunk-driving ... to recent statistics, and a $232,000 grant from the California ... Safety Administration to UC Irvine,s Health Education Center is ... with the RADD College DUI Awareness Program, UCI has organized ...
... -- Takemi Tanaka, Ph.D., of Thomas Jefferson University,s School ... , received a $50,000 grant toward her breast cancer research, ... for Breast and Cervical Cancer Research" initiative. The ... who choose to contribute all or part of their state ...
Cached Medicine News:Health News:Lupus, Rheumatoid Arthritis Linked to Fertility Woes, Miscarriage 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 2Health News:New Blood Thinner May Prevent Blood Clots During Cancer Treatment 3Health News:Stop-Smoking Drug May Also Curb Problem Drinking 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 2Health News:Many U.S. Teens Hit the Road Without Driver's Ed: Survey 3Health News:UCI leads multicampus collaboration to reward use of designated drivers 2Health News:Taxpayers give back for cancer: Jefferson researcher awarded 'Refunds for Research' grant 2
... fixation. Completely resorbable, it presented surgeons with ... the most thoroughly proven product of its ... with system enhancements that make it even ... system means that application of this proven ...
... The intra-operative MR system ... intra-operative tool for radiologists ... goal of the system ... valuable adjunct to standard ...
... ultrasound A-scan Sonomed-315 is intended for visualization ... detection of midline shifts in the brain, ... and easy to use, the Sonomed-315 offers ... A-scanning mode allows to identify the anatomic ...
... With Plasmaseal's Proteus device the two steps ... is injected into Proteus' single use disposable ... base unit. The operator touches a button, ... is separated by centrifugation. Then the integral ...
Medicine Products: